The Toxicity and Biological Functions of Statins During Treatments
DOI:
https://doi.org/10.54097/df3jp957Keywords:
Statins; toxicity; biological functions; CVDs.Abstract
Cardiovascular morbidity and mortality are reduced by statins, which are drugs that lower cholesterol and reduce LDL-c. Statins function by competitively blocking the primary rate-limiting enzyme in HMG-CoA reductase, inhibiting it so that no substrate can enter and no HMG-CoA can be converted to mevalonic acid. Statins are by far the mainstay of majority and minority prevention of atherosclerotic cardiovascular disease, but they have also been linked to a variety of side effects. Statin therapy should be discontinued because of muscle symptoms associated with it and the development of new-onset type 2 diabetes as a side effect of statins is a serious issue and the pathogenesis of it is still unclear. This paper focuses on the biological function of statins and their toxicity, i.e. the mechanisms responsible for the adverse effects. It is intended to inform the study of the mechanisms of toxicity episodes of statins. Some of the mechanisms of toxicity onset of statins cannot be determined at this time, various patient populations could be studied in future studies to explore the side effects of statins.
Downloads
References
Ward, N.C., Watts, G.F. and Eckel, R.H. Statin Toxicity. Circulation Research, 2019, 124(2), pp.328–350.
Patrick du Souich, Ghislaine Roederer, Robert Dufour, Myotoxicity of statins: Mechanism of action, Pharmacology & Therapeutics. 2017, pp. 1-16
Jiang, W.; Hu, J.-W.; et al. Statins: A repurposed drug to fight cancer. J. Exp. Clin. Cancer Res. 2021, 40, 241.
Juarez, D.; Fruman, D.A. Targeting the Mevalonate Pathway in Cancer. Trends Cancer. 2021, 7, 525–540.
Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam. Clin. Pharmacol. 2005, 19, 117–125.
Beckwitt, C.H.; Shiraha, K.; Wells, A. Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. PLoS ONE. 2018, 13, e0197422.
Gu, Q.; Paulose-Ram, R.; Burt, V.L.; Kit, B.K. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. In NCHS Data Brief; Centers for Disease Control and Prevention: Atlanta, GA, USA, 2014, pp. 1–8.
E.S. Stroes, P.D. Thompson, A. Corsini, et al.Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J. 2015, 36, pp. 1012-1022
Sabine Lotteau, Niklas Ivarsson, Zhaokang Yang, Damien Restagno, John Colyer, Philip Hopkins, Andrew Weightman, Koichi Himori, Takashi Yamada, Joseph Bruton, Derek Steele, Håkan Westerblad, Sarah Calaghan, A Mechanism for Statin-Induced Susceptibility to Myopathy, JACC: Basic to Translational Science. 2019, pp. 509-523.
A.M. Bellinger, S. Reiken, C. Carlson, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle Nat Med. 2009, 15, pp. 325-330.
D.C. Andersson, M.J. Betzenhauser, S. Reiken, et al. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging Cell Metab. 2011, 14, pp. 196-207
S. Reiken, A. Lacampagne, H. Zhou, et al. PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure J Cell Biol. 2003, 160, pp. 919-928.
W.J. Durham, P. Racena-Parks, et al. RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice Cell. 2008, 133, pp. 53-65
Karahalil, B. et al. Hepatotoxicity associated with statins. Arh Hig Rada Toksikol. 2017, 68, 254-260.
Chalasani, N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepat 2005, 41, 690-695.
Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012, 56(2):374-380
Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007, 6(6):673-684
Averbukh LD, Turshudzhyan A, Wu DC, Wu GY. Statin-induced Liver Injury Patterns: A Clinical Review. J Clin Transl Hepatol. 2022;10(3):543-552.
Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, Norata GD. Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochim Biophys Acta Mol Basis Dis. 2019, 1865:2149–56.
Zhu Y, Liu Q, Zhou Z, Ikeda Y. PDX1, neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther. 2017. 8:240.
Takei S, Nagashima S, Takei A, Yamamuro D, Wakabayashi T, Murakami A, et al. β-cell-specific deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase causes overt diabetes due to reduction of β-cell mass and impaired insulin secretion. Diabetes.2020, 69:2352–63.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
